<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03675880</url>
  </required_header>
  <id_info>
    <org_study_id>ZK-TAB-201709</org_study_id>
    <nct_id>NCT03675880</nct_id>
  </id_info>
  <brief_title>TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects</brief_title>
  <official_title>A Phase Ⅰ Clinical Study of TAB014 in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with secondary wet age-related macular degeneration(AMD) or recurrent subfoveal
      choroidal neovascularization (CNV) in only one study eye will be enrolled into the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The screening period was 28 days. The classification of CNV will be determined by Fundus
      Fluorescein Angiography ( FFA ) at the study centers. Subjects will receive intravitreal
      injections of TAB014 Monoclonal Antibody Injection in one eye ( the study eye ). Subjects
      will only receive single intravitreal dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity associated with TAB014 treatment (possibly, probably, or definitively) occurs within 28 days after a single dose of TAB014.</measure>
    <time_frame>Within 12 weeks after administration</time_frame>
    <description>Describe the impairment of vision by examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicity and adverse reaction</measure>
    <time_frame>Within 12 weeks after administration</time_frame>
    <description>To Assess the dose-limiting toxicity and adverse reaction of TAB014 Monoclonal Antibody Injection.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>AMD</condition>
  <arm_group>
    <arm_group_label>1.25mg(0.05ml) single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be treated with TAB014 1.25mg(0.05ml) single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.00mg(0.08ml) single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be treated with TAB014 2.00mg(0.08ml) single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.50mg(0.10ml) single-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be treated with TAB014 2.50mg(0.10ml) single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.25mg(0.05ml) multiple-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be treated with TAB014 1.25mg(0.05ml) multiple-dose after 1.25mg(0.05ml) single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.00mg(0.08ml) multiple-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be treated with TAB014 2.00mg(0.08ml) multiple-dose after 2.00mg(0.08ml) single-dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.50mg(0.10ml) multiple-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight subjects will be treated with TAB014 2.50mg(0.10ml) multiple-dose after 2.50mg(0.10ml) single-dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAB014</intervention_name>
    <description>TAB014 of 1.25mg(0.05ml)、2.00mg(0.08ml)、2.50mg(0.10ml)</description>
    <arm_group_label>1.25mg(0.05ml) multiple-dose</arm_group_label>
    <arm_group_label>1.25mg(0.05ml) single-dose</arm_group_label>
    <arm_group_label>2.00mg(0.08ml) multiple-dose</arm_group_label>
    <arm_group_label>2.00mg(0.08ml) single-dose</arm_group_label>
    <arm_group_label>2.50mg(0.10ml) multiple-dose</arm_group_label>
    <arm_group_label>2.50mg(0.10ml) single-dose</arm_group_label>
    <other_name>TAB014 monoclonal antibody injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects, 50 years of age or older.

          2. Have secondary actively Age-related macular degeneration(wAMD) or recurrent CNV
             including subfoveal type and extrafoveal type in the only study eye.

          3. If have occult CNV or partial classic CNV lesions will be enrolled into the study.

          4. The total CNV area(both classic and occult lesion) including lesion area are more than
             or equal to 50% total lesion areas.

          5. The total lesion area is less than or equal to 12 disk area (DA).

          6. Volunteer to participate in the study and able to read and understand informed consent
             and provide written informed consent.

        Exclusion Criteria:

        1. Prior and concomitant therapy

          1. Prior use of verteporfin, external beam radiation therapy or transpupillary
             thermotherapy(TTT) in 6 months period of the screening.

          2. Subjects that have received angiogenesis inhibitors therapy, such as Pegaptanib
             Sodium, Lucentis, Bevacizumab, Bevacizumab (RETAANE) or protein kinase C inhibitor in
             either eye are participating in any other research study within the last 6 months
             before the screening.

          3. Subjects that have received other intravitreal injection therapy(Corticosteroids or
             device implants) in the study eye within the last 6 months before the screening.

          4. Subjects that have treated with focal argon laser photocoagulation for macular edema
             in study eye within the last 6 months before the screening.

          5. Subjects that have undergone previous photocoagulation of the retina(extrafoveal
             areas) in the study eye within the last 3 months before the screening.

          6. Subjects with a history of vitreoretinal surgery in the study eye.

          7. Subjects that have undergone previous AMD surgery or other surgical interventions.

          8. Subjects that have participated in other study of treatment with study drug(except for
             vitamins and minerals) within the last 3 months before the screening.

        2. lesion features:

          1. Area of bleeding under the retina 50% total lesion areas or 4 disk area.

          2. Subfoveal fibrosis.

          3. CNV that be caused by the oter reasons in either eye,such as ocular histoplasmosis
             syndrome, craniocerebral trauma or pathological myopia.

          4. retinal pigment epithelium (RPE) tears. 3. concomitant eye disease:

        1) Subjects with ongoing any concomitant eye disease(i.e cataracts or diabetic retinopathy)
        by the investigator's judgment:

          1. Vision loss caused by these diseases to cause interference with medical or operation
             intervention during 3 months study.

          2. Best corrected visual acuity (BCVA) loss at least of 2 lines Snellen equivalents
             (ETDRS 10 letters) at 3 months, if don't treat the disease.

             2) Subjects who are active endophthalmitis(with micro level or above). 3) Subjects
             with ongoing internal vitreous hemorrhage. 4) Subjects with Rhegmatogenous retinal
             detachment or history of macular holes stage 3/4.

             5) Subjects with history of idiopathic uveitis or autoimmune uveitis in either eye 6)
             Subjects with ongoing infectious conjunctivitis, infectious keratitis, infectious
             scleral or endophthalmitis in either eye.

             7) Subjects that have undergone previous intraocular surgery (including cataract
             surgery ) within the last 3 months before the screening.

             8) Subjects who are uncontrolled glaucoma(defined as intraocular pressure [IOP] 30
             mmHg, even when treated with anti-glaucoma drugs).

             9) Subjects with history of glaucoma filtration surgery. 4. concomitant system
             disease:

               1. Subjects of child bearing ages will undergo pregnancy testing.

               2. Subjects with ongoing severe hepatic and renal disease or abnormal liver and
                  kidney function(ALT, Angiotensin sensitivity test (AST) ≥1.5 ULN, Cr, UREA＞ULN)
                  at Baseline.

               3. Patients with other disease history,such as uncontrolled diabetics or
                  hypertension, periinfarction within the last 6 months,as well as not suitable for
                  this study per the investigator's judgment.

               4. Subjects with ongoing systemic infection therapy. 5.other:

               1. Subjects with history of fluoresceins allergy.

               2. Not get enough quality of fundus photography and fluorescein angiography used by
                  reading and analysing from the reading center.

               3. Unwilling and not be able to return for all study visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>youxin chen, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Peking Union Medical College Hospital of Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>youxin chen, PHD</last_name>
    <phone>010-69156699</phone>
    <email>chenyouxinpumch@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>yan sun, master</last_name>
    <phone>010-69158355</phone>
    <email>xieheyaoli@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>youxin chen, PHD</last_name>
      <phone>010-69156699</phone>
      <email>chenyouxinpumch@163.com</email>
    </contact>
    <contact_backup>
      <last_name>yan sun, master</last_name>
      <phone>010-69158355</phone>
      <email>xieheyaoli@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):1-11. doi: 10.1007/s00417-008-0952-y. Epub 2008 Oct 9. Review.</citation>
    <PMID>18843500</PMID>
  </results_reference>
  <results_reference>
    <citation>Jyothi S, Chowdhury H, Elagouz M, Sivaprasad S. Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. Eye (Lond). 2010 May;24(5):816-24. doi: 10.1038/eye.2009.219. Epub 2009 Aug 14. Review.</citation>
    <PMID>19680279</PMID>
  </results_reference>
  <results_reference>
    <citation>Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin. 2011 Jul;27(7):1465-75. doi: 10.1185/03007995.2011.585394. Epub 2011 May 31. Review.</citation>
    <PMID>21623685</PMID>
  </results_reference>
  <results_reference>
    <citation>Li J, Zhang H, Sun P, Gu F, Liu ZL. Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients. Int J Ophthalmol. 2013 Apr 18;6(2):169-73. doi: 10.3980/j.issn.2222-3959.2013.02.12. Print 2013.</citation>
    <PMID>23638418</PMID>
  </results_reference>
  <results_reference>
    <citation>Kodjikian L, Decullier E, Souied EH, Girmens JF, Durand EE, Chapuis FR, Huot L. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials. Graefes Arch Clin Exp Ophthalmol. 2014 Oct;252(10):1529-37. doi: 10.1007/s00417-014-2764-6. Epub 2014 Aug 22. Review.</citation>
    <PMID>25142373</PMID>
  </results_reference>
  <results_reference>
    <citation>Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006 Mar;26(3):257-61.</citation>
    <PMID>16508423</PMID>
  </results_reference>
  <results_reference>
    <citation>Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA Jr. Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina. 2006 Oct;26(8):882-8.</citation>
    <PMID>17031287</PMID>
  </results_reference>
  <results_reference>
    <citation>Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006 Mar;26(3):262-9.</citation>
    <PMID>16508424</PMID>
  </results_reference>
  <results_reference>
    <citation>Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007 Oct;114(10):1860-7. Epub 2007 Aug 15.</citation>
    <PMID>17698196</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 5, 2018</study_first_submitted>
  <study_first_submitted_qc>September 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2018</study_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

